hit-to-lead studies: the discovery of potent, orally bioavailable thiazolopyrimidine cxcr2 receptor...
Post on 06-Jun-2016
213 Views
Preview:
TRANSCRIPT
2006
Fused pyrimidine derivativesR 0515 Hit-to-Lead Studies: The Discovery of Potent, Orally Bioavailable Thiazolopyri-
midine CXCR2 Receptor Antagonists. — A hit-to-lead optimization program on the high throughput screening hit (Ia) results in the discovery of potent CXCR2 receptor antagonist (Ic). — (BAXTER*, A.; COOPER, A.; KINCHIN, E.; MOAKES, K.; UNITT, J.; WALLACE, A.; Bioorg. Med. Chem. Lett. 16 (2006) 4, 960-963; AstraZeneca R&D Charnwood, Loughborough, Leicestershire LE11 5RH, UK; Eng.) — D. Singer
21- 157
top related